HOME >> MEDICINE >> NEWS
Neoadjuvant and adjuvant systemic therapy for breast cancer give equivalent survival, study finds

The timing of systemic therapy--chemotherapy or endocrine therapy--for breast cancer does not appear to affect survival or disease progression. However, women who receive systemic therapy and radiation therapy without surgery may be more likely to experience a recurrence of their cancer compared with women treated with chemotherapy later, according to a new study in the February 2 issue of the Journal of the National Cancer Institute.

Neoadjuvant--also called preoperative or primary--systemic therapy for breast cancer may result in local tumor regression or even in a complete tumor response and may lead to a more limited extent of surgery--from radical mastectomy to some type of breast-conserving surgery--without risking patient survival. For these reasons, interest in the use of neoadjuvant therapy has been increasing.

To investigate how the timing of systemic therapy affects breast cancer outcomes, John P.A. Ioannidis, M.D., of the University of Ioannina School of Medicine in Greece, and colleagues performed a meta-analysis of nine randomized trials that had included nearly 4,000 breast cancer patients. The patients had been treated with systemic therapy either before or after surgery and/or radiation therapy.

There was no difference between neoadjuvant and adjuvant systemic therapy in terms of death, disease progression, or distant disease recurrence. However, neoadjuvant therapy was associated with a 22% increased risk of loco-regional disease recurrence compared with adjuvant therapy. This risk was higher (53%) when radiation therapy was used without surgery.

"[T]his meta-analysis demonstrates the equivalence of neoadjuvant and adjuvant treatments for breast cancer in terms of survival, disease progression, and distant recurrence and shows that an increased risk of loco-regional disease recurrence is associated with neoadjuvant treatment, especially when primary systemic treatment is not accompanied by any surgical interve
'"/>

Contact: Sarah L. Zielinski
jncimedia@oupjournals.org
301-841-1287
Journal of the National Cancer Institute
1-Feb-2005


Page: 1 2

Related medicine news :

1. MRI better than current standard in assessing neoadjuvant chemotherapy for breast cancer
2. Updated adjuvant data presented at SABCS show 30 percent reduction in recurrence
3. Different methods of adjuvant chemotherapy for colorectal cancer have similar outcomes
4. Study supports tailoring adjuvant therapy for early-stage breast cancer
5. Nordic collaboration gives new insights into adjuvant chemotherapy
6. Tumor-targeted immune cells cure prostate cancer in mice without causing systemic immune suppression
7. A blood test may reveal systemic factors that relate to periodontal disease, especially in men
8. Important information to consider about non-systemic cholesterol lowering agents
9. Study shows patch therapy may be as effective as oral medications
10. Novel therapy tested in mice could chase away cat allergies
11. Drug therapy may be comparable to invasive cardiac procedures for elderly patients with heart attack

Post Your Comments:
(Date:9/4/2015)... ... September 04, 2015 , ... Having access to a ... led to an increasing amount of unnecessary emergency room visits which affects hospitals’ abilities ... the country’s health bill. Fortunately, a solution to alleviate this problem has recently presented ...
(Date:9/4/2015)... ... 2015 , ... Lalonde Gordon ran a 44.64 seconds scorcher in the third ... men’s 400 meters final, with an impressive 44.89 seconds at the 2015 North American, ... Rica in August 2015. The 44.64 time is a new NACAC Championship record. ...
(Date:9/4/2015)... DC (PRWEB) , ... September 04, 2015 , ... ... they all pale in comparison to settlements under the Stark physician self-referral law. ... an upcoming Sept. 17 webinar from Atlantic Information Services, Inc. (AIS), will detail ...
(Date:9/4/2015)... NC (PRWEB) , ... September 04, 2015 , ... ... filtration products, has a Labor Day offer that cannot be passed up. ... stock up on necessary air and water filtration product replacements. Take advantage of ...
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... Friday night, ... IL hosting Generation Rescue’s A Night of Hope event supporting families affected by autism, ... and Rowena and Joe Salas, joined together at the Oscar Swan Inn to support ...
Breaking Medicine News(10 mins):Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 3Health News:Lalonde Gordon’s Recipe Brings Home the Gold 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 3Health News:Sept. 17 Webinar to Offer Best Practices for Physician Contracts 2Health News:FiltersFast.com Wows with a Long Labor Day Weekend Shipping Offer 2Health News:Jenny McCarthy & Donnie Wahlberg Help Raise Over $200,000 For Generation Rescue’s ‘Night Of Hope’ Chicago Charity Event 2
(Date:9/3/2015)... NEW YORK , Sept. 3, 2015 About ... in dryness of eyes due to deficient tear production ... This syndrome is of two types: aqueous tear deficient ... deficient dry eye, lacrimal glands do not produce enough ... eye. Meibomian glands secrete lipids to slow tear evaporation ...
(Date:9/3/2015)... Sept. 3, 2015  WellCare Health Plans, Inc. (NYSE: ... , senior vice president and chief financial officer, is ... Healthcare Conference on Wednesday, September 9, 2015, at 9:25 ... webcast live. In addition, a replay of the webcast ... broadcast. Both the live broadcast and the replay will ...
(Date:9/3/2015)... and ALISO VIEJO, Calif. ... (NYSE: AGN ), a leading global pharmaceutical ... medical device company focused on developing ocular implants ... today announced that they have entered into an ... an all-cash transaction.  Under the terms of the ...
Breaking Medicine Technology:Global Dry Eye Syndrome Market 2015-2019 2Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 2Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 3Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 4Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 5Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 6
Cached News: